Cargando…
Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance
The bacterial metallo-β-lactamases (MBLs) catalyze the inactivation of β-lactam antibiotics. Identifying novel pharmacophores remains crucial for the clinical development of additional MBL inhibitors. Previously, 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid, hereafter referred to as 1,2-HPT-6-CO...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514461/ https://www.ncbi.nlm.nih.gov/pubmed/37549809 http://dx.doi.org/10.1016/j.jbc.2023.105135 |
_version_ | 1785108733607542784 |
---|---|
author | Thoden, James B. Benin, Bogdan M. Priebe, Adam Shin, Woo Shik Muthyala, Ramaiah Sham, Yuk Yin Holden, Hazel M. |
author_facet | Thoden, James B. Benin, Bogdan M. Priebe, Adam Shin, Woo Shik Muthyala, Ramaiah Sham, Yuk Yin Holden, Hazel M. |
author_sort | Thoden, James B. |
collection | PubMed |
description | The bacterial metallo-β-lactamases (MBLs) catalyze the inactivation of β-lactam antibiotics. Identifying novel pharmacophores remains crucial for the clinical development of additional MBL inhibitors. Previously, 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid, hereafter referred to as 1,2-HPT-6-COOH, was reported as a low cytotoxic nanomolar β-lactamase inhibitor of Verona-integron-encoded metallo-β-lactamase 2, capable of rescuing β-lactam antibiotic activity. In this study, we explore its exact mechanism of inhibition and the extent of its activity through structural characterization of its binding to New Delhi metallo-β-lactamase 4 (NDM-4) and its inhibitory activity against both NDM-1 and NDM-4. Of all the structure-validated MBL inhibitors available, 1,2-HPT-6-COOH is the first discovered compound capable of forming an octahedral coordination sphere with Zn2 of the binuclear metal center. This unexpected mechanism of action provides important insight for the further optimization of 1,2-HPT-6-COOH and the identification of additional pharmacophores for MBL inhibition. |
format | Online Article Text |
id | pubmed-10514461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-105144612023-09-23 Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance Thoden, James B. Benin, Bogdan M. Priebe, Adam Shin, Woo Shik Muthyala, Ramaiah Sham, Yuk Yin Holden, Hazel M. J Biol Chem Research Article The bacterial metallo-β-lactamases (MBLs) catalyze the inactivation of β-lactam antibiotics. Identifying novel pharmacophores remains crucial for the clinical development of additional MBL inhibitors. Previously, 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid, hereafter referred to as 1,2-HPT-6-COOH, was reported as a low cytotoxic nanomolar β-lactamase inhibitor of Verona-integron-encoded metallo-β-lactamase 2, capable of rescuing β-lactam antibiotic activity. In this study, we explore its exact mechanism of inhibition and the extent of its activity through structural characterization of its binding to New Delhi metallo-β-lactamase 4 (NDM-4) and its inhibitory activity against both NDM-1 and NDM-4. Of all the structure-validated MBL inhibitors available, 1,2-HPT-6-COOH is the first discovered compound capable of forming an octahedral coordination sphere with Zn2 of the binuclear metal center. This unexpected mechanism of action provides important insight for the further optimization of 1,2-HPT-6-COOH and the identification of additional pharmacophores for MBL inhibition. American Society for Biochemistry and Molecular Biology 2023-08-06 /pmc/articles/PMC10514461/ /pubmed/37549809 http://dx.doi.org/10.1016/j.jbc.2023.105135 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Thoden, James B. Benin, Bogdan M. Priebe, Adam Shin, Woo Shik Muthyala, Ramaiah Sham, Yuk Yin Holden, Hazel M. Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance |
title | Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance |
title_full | Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance |
title_fullStr | Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance |
title_full_unstemmed | Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance |
title_short | Characterization of a novel inhibitor for the New Delhi metallo-β-lactamase-4: Implications for drug design and combating bacterial drug resistance |
title_sort | characterization of a novel inhibitor for the new delhi metallo-β-lactamase-4: implications for drug design and combating bacterial drug resistance |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514461/ https://www.ncbi.nlm.nih.gov/pubmed/37549809 http://dx.doi.org/10.1016/j.jbc.2023.105135 |
work_keys_str_mv | AT thodenjamesb characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance AT beninbogdanm characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance AT priebeadam characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance AT shinwooshik characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance AT muthyalaramaiah characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance AT shamyukyin characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance AT holdenhazelm characterizationofanovelinhibitorforthenewdelhimetalloblactamase4implicationsfordrugdesignandcombatingbacterialdrugresistance |